Perhaps most impressive, the combined company’s revenues will be just shy of $10 million, and they will have more than $56 million in the bank. The combined company, operating under the Numinus’ name and leadership team, will operate 13 wellness clinics across North America, four research sites, and one bioanalytical laboratory.
Novamind 5 trial#
The company has eight ketamine clinics throughout the USA, and they announced recently that they will be hosting a Usona Phase 2 clinical trial treating Major Depressive Disorder with psilocybin-therapy and a MindMed Phase 2b trial treating Generalized Anxiety Disorder with LSD therapy. Novamind, while much smaller with a market cap just shy of $15 million (CAD), is also a leader in certain respects. They have a market cap north of $100 million (CAD), are working with MAPS on treating PTSD with MDMA-therapy, they’re running a compassionate access trial treating Substance Use Disorders with psilocybin-therapy, they’re operating five therapy clinics in Canada, and they have two research facilities and a bioanalytical laboratory. When the transaction is finalized, each Novamind share you own will automatically be transformed into 0.84 of a Numinus share.Įven before the acquisition, Numinus was already a top 10 player in the psychedelic medicines field. If you currently hold Novamind stock, you do not need to do anything. When the transaction is completed, Novamind shareholders will own around 18% of Numinus.
![novamind 5 novamind 5](http://a2.mzstatic.com/us/r30/Purple/v4/d0/e6/ad/d0e6addb-d95e-95b7-d1aa-bc36cf8889e7/NMAppIcon.512x512-75.png)
This means Numinus is offering a premium of 51% to Novamind shareholders, based on the 20-day volume-weighted average price of their stock. The acquisition will be done in stock, and shareholders of Novamind will receive 0.84 of a common share of Numinus per Novamind share held, implying an offer price of $0.44 per Novamind share. Psychedelic stock investors woke up to some major news today: Numinus Wellness (TSX: NUMI) (OTCQX: NUMIF) announced that they are acquiring Novamind Inc.